+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pharmacokinetic comparison of amlodipine adipate/valsartan fixed-dose combination with amlodipine besylate/valsartan fixed-dose combination in healthy volunteers



Pharmacokinetic comparison of amlodipine adipate/valsartan fixed-dose combination with amlodipine besylate/valsartan fixed-dose combination in healthy volunteers



International Journal of Clinical Pharmacology and Therapeutics 53(1): 66-74



The aim of this study was to compare pharmacokinetic characteristics of fixed-dose combination (FDC) of two different salt form of amlodipine, amlodipine adipate/valsartan and amlodipine besylate/ valsartan, in healthy Korean volunteers under fasting conditions. A randomized, open-label, single-dose, two-treatment, two-way crossover study with a 14-day wash-out period was conducted. Plasma samples were collected for up to 144 hours for amlodipine and 24 hours for valsartan. Plasma concentrations of amlodipine and valsartan were analyzed using a validated ultra-performance liquid chromatography tandem mass-spectrometry. A non-compartmental method was used to calculate pharmacokinetic parameters. Vital signs and adverse events were monitored and physical examinations, laboratory tests, and electrocardiograms were conducted to evaluate safety. 44 subjects completed the study. The 90% CIs for the geometric mean ratio of Cmax and the AUC0-t were 93.5 - 100.4% and 93.2 - 98.3% for amlodipine, and 92.1 - 121.3% and 94.1 - 115.2% for valsartan, respectively. 17 adverse events occurred in 15 subjects during the study; 5 and 7 adverse drug reactions from the 5 and 6 subjects were considered to probably be related to the test and reference treatments respectively. All adverse drug reactions were in line with those known for the reference drug. All subjects recovered fully with no sequelae. A FDC of amlodipine adipate/valsartan and amlodipine besylate/valsartan combination tablets met the regulatory criteria for bioequivalence. In addition, no significant difference was observed in the safety assessments between two treatments. Thus, the newly developed FDC of amlodipine adipate/valsartan seems to be interchangeable with amlodipine besylate valsartan combination.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054956842

Download citation: RISBibTeXText

PMID: 25034618

DOI: 10.5414/cp202045


Related references

Pharmacokinetic comparison of 2 fixed-dose combination tablets of amlodipine and valsartan in healthy male Korean volunteers: a randomized, open-label, 2-period, single-dose, crossover study. Clinical Therapeutics 35(7): 934-940, 2013

Effect of food on the oral bioavailability of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide fixed dose combination tablets in healthy subjects. Clinical Pharmacology in Drug Development 3(6): 487-492, 2014

Clinical Effectiveness And Safety Of A Fixed-Dose Combination Of Ramipril Plus Felodipine Er In Comparison With A Fixed-Dose Combination Of Trandolapril Plus Verapamil Sr And Valsartan Plus Amlodipine In Treatment Of An Essential Arterial Hypertension. Journal of Hypertension 29: e282-e283, 2011

Amlodipine/Valsartan: fixed-dose combination in hypertension. Drugs 68(3): 373-381, 2008

Electrospun fixed dose formulations of amlodipine besylate and valsartan. International Journal of Pharmaceutics 549(1-2): 446-455, 2018

Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension. American Journal of Cardiovascular Drugs 9(6): 411-418, 2009

Amlodipine and valsartan as components of a rational and effective fixed-dose combination. Vascular Health and Risk Management 5(1): 165-174, 2009

Investigation of a potential pharmacokinetic interaction between perindopril arginine and amlodipine when administered as a single perindopril/amlodipine fixed-dose combination tablet in healthy Chinese male volunteers. International Journal of Clinical Pharmacology and Therapeutics 54(1): 43-51, 2016

Amlodipine + valsartan + hydrochlorothiazide. A 3-drug fixed-dose combination for hypertension: too many drawbacks. Prescrire International 20(114): 67-67, 2011

Indirect treatment comparison between fixed-dose-combinations of amlodipine/losartan and amlodipine/valsartan in blood pressure control. International Journal of Clinical Practice 68(2): 163-172, 2014

Comparison of amlodipine/valsartan fixed-dose combination therapy and conventional therapy. Managed Care 19(7): 36-42, 2010

Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan. Clinical Drug Investigation 30(9): 625-641, 2010

Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan. Journal of Clinical Hypertension 17(1): 51-58, 2015

The effect of fixed-dose combination of valsartan and amlodipine on nighttime blood pressure in patients with non-dipper hypertension. Turk Kardiyoloji Dernegi Arsivi 44(5): 404-413, 2016

Efficacy and tolerability of a switch to fixed-dose combination therapy with amlodipine besylate/benazepril hydrochloride after monotherapy with amlodipine besylate: Data from the African-American subpopulation of a practice-based, open-label study (the LOGIC study). Current Therapeutic Research, Clinical and Experimental 65(2): 138-148, 2004